Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2011 | Original Paper

Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer

Authors: Christine Schröder, Isabell Witzel, Volkmar Müller, Sylke Krenkel, Ralph M. Wirtz, Fritz Jänicke, Udo Schumacher, Karin Milde-Langosch

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2011

Abstract

Purpose

The intercellular adhesion molecule (ICAM)-1 is expressed on many cell types including endothelial cells and different cancer cell entities. Experimental data strongly indicate that ICAM-1 can activate intracellular signalling pathways in cancer cells leading to enhanced cell motility, invasion and metastasis. Yet, little is known about the role of ICAM-1 expression during malignant progression in breast cancer patients.

Methods

We investigated ICAM-1 protein and mRNA expression in two partly overlapping cohorts of breast cancer patients. ICAM-1 protein was detected by Western blot analysis in 104 cases and verified by immunohistochemistry. Additionally, ICAM-1 mRNA microarray data from 169 tumours were analysed.

Results

With both methods, high ICAM-1 expression was significantly associated with a poorly differentiated phenotype, a negative estrogen receptor (ER) status and positive lymph node involvement. In addition, there was a significant prognostic impact of ICAM-1 protein overexpression on recurrence-free survival (HR = 2.82, P = 0.023), which was most pronounced in ER-negative tumours. ICAM-1 mRNA overexpression was associated with high urokinase plasminogen activator (uPA) and uPA-inhibitor protein 1 (PAI 1) protein and mRNA levels as well as high Ki67 protein and vascular endothelial growth factor (VEGF) mRNA expression.

Conclusions

In our group of patients, ICAM-1 expression was associated with a more aggressive tumour phenotype. Because of its association with malignant progression, ICAM-1 might represent a new target in the treatment of breast cancer patients.

Abdelrazik N, Fouda M et al (2008) Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma. Med Princ Pract 17:233–238PubMedCrossRef

Ahmed M, Kundu GC (2010) Osteopontin selectively regulates p70S6 K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer 9:101PubMedCrossRef

Brooks KJ, Coleman EJ et al (2008) The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. Int J Cancer 123:2438–2445PubMedCrossRef

Christiansen I, Gidlof C et al (1994) Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 84:3010–3016PubMed

Dong C, Robertson GP (2009) Immunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development. Biorheology 46:265–279PubMed

Fox SB, Turner GD et al (1995) The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol 177:369–376PubMedCrossRef

Harning R, Mainolfi E et al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51:5003–5005PubMed

Hutchins D, Steel CM (1994) Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 58:80–84PubMedCrossRef

Jänicke F, Pache L et al (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plaminogen activator inhibitor type I. Cancer Res 54:2527–2530PubMed

Jimenez D, Roda-Navarro P et al (2005) Contribution of N-linked glycans to the conformation and function of intercellular adhesion molecules (ICAMs). J Biol Chem 280:5854–5861PubMedCrossRef

Kostler WJ, Tomek S et al (2001) Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunol Immunother 50:483–490PubMed

Ksiazek K, Mikula-Pietrasik J et al (2010) Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int J Cancer 127:293–303PubMed

Lawson C, Wolf S (2009) ICAM-1 signaling in endothelial cells. Pharmacol Rep 61:22–32PubMed

Mace EM, Zhang J et al (2010) Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells. Blood 116:1272–1279PubMedCrossRef

Matory YL, Dorfman DM et al (1999) Treatment of established tumor is associated with ICAM-1 upregulation and reversed by CD8 depletion in a tumor necrosis factor-alpha gene transfected mouse mammary tumor. Pathobiology 67:186–195PubMedCrossRef

Mehta BA, Collard HR et al (1994) The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis. Cell Immunol 155:95–110PubMedCrossRef

O’Hanlon DM, Fitzsimons H et al (2002) Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38:2252–2257PubMedCrossRef

Ogawa Y, Hirakawa K et al (1998) Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 4:31–36PubMed

Otto VI, Damoc E et al (2006) N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry. Glycobiology 16:1033–1044PubMedCrossRef

Rahn JJ, Chow JW et al (2005) MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 22:475–483PubMedCrossRef

Regidor PA, Callies R et al (1998) Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera. Eur J Gynaecol Oncol 19:377–383PubMed

Regimbald LH, Pilarski LM et al (1996) The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244–4249PubMed

Roland CL, Harken AH et al (2007) ICAM-1 expression determines malignant potential of cancer. Surgery 141:705–707PubMedCrossRef

Rosette C, Roth RB et al (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26:943–950PubMedCrossRef

Schröder C, Schumacher U et al (2010) The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer 46:1650–1660PubMedCrossRef

Strell C, Lang K et al (2010) Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 316:138–148PubMedCrossRef

Toiyama Y, Miki C et al (2008) Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol 15:1617–1624PubMedCrossRef

Witzel ID, Milde-Langosch K et al (2010) Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol 136:1709–1718PubMedCrossRef

Yang SF, Chen MK et al (2010) Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem 285:29808–29816PubMedCrossRef

Yuan K, Kucik D et al (2008) Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties. Int J Oncol 32:797–807PubMed

Title: Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer
Authors: Christine Schröder
Isabell Witzel
Volkmar Müller
Sylke Krenkel
Ralph M. Wirtz
Fritz Jänicke
Udo Schumacher
Karin Milde-Langosch
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-0984-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2011

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Second-line chemotherapy in patients with primary unknown cancer

Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers

Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials